Content about paclitaxel

October 26, 2012
Chemotherapy drug shows "significant" improvement in melanoma patients in late-stage trial

A Swiss subsidiary of drug maker Celgene Corp. said its chemotherapy drug produced "significant" improvement in progression-free survival in patients with a deadly skin cancer that had spread elsewhere in the body.

BOUDRY, Switzerland — A Swiss subsidiary of drug maker Celgene Corp. said its chemotherapy drug produced "significant" improvement in progression-free survival in patients with a deadly skin cancer that had spread elsewhere in the body.

October 12, 2012
FDA approves Celgene lung-cancer drug

The Food and Drug Administration has approved an injected drug for lung cancer made by Celgene, the company said Friday.

SUMMIT, N.J. — The Food and Drug Administration has approved an injected drug for lung cancer made by Celgene, the company said Friday.

Celgene announced the approval of Abraxane (paclitaxel) protein-bound particles for injectable suspension, for the first-line treatment of non-small cell lung cancer that has advanced locally or spread to other parts of the body, in combination with carboplatin, for patients who are not candidates for curative surgery or radiation therapy.

September 28, 2011
Sagent's chemotherapy drug enters market

Sagent Pharmaceuticals has launched its new chemotherapy drug.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched its new chemotherapy drug.

Sagent sent that its paclitaxel injection USP is available in 30-mg, 100-mg and 300-mg latex-free, multi-dose vials. Paclitaxel is indicated for use alone or with other drugs to treat ovarian cancer, breast cancer, non-small cell lung cancer and AIDS-related Kaposi's sarcoma, Sagent said.

January 19, 2011
Genentech appeals FDA's plan to pull Avastin off market

Drug maker Genentech is hoping to keep a breast cancer treatment on the market as the Food and Drug Administration considers whether to revoke its approval for the disease, according to published reports.

NEW YORK — Drug maker Genentech is hoping to keep a breast cancer treatment on the market as the Food and Drug Administration considers whether to revoke its approval for the disease, according to published reports.

The San Francisco Business Times reported Tuesday that Genentech, part of Swiss drug maker Roche, is appealing the FDA’s plan to revoke approval for the drug Avastin (bevacizumab) as a first-line treatment for advanced HER2-negative breast cancer in combination with paclitaxel chemotherapy.

December 8, 2010
Decision Resources: J&J, Merck chemotherapy drugs will emerge as go-to second-line treatments

Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

BURLINGTON, Mass. — Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

July 20, 2010
FDA advisory committee recommends limiting use of Genentech breast cancer drug

A Food and Drug Administration advisory committee has voted to recommend limiting use of a...